Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Turning Point Therapeutics, Inc.
Scientific Title
A Phase 1/2 Study of TPX-0131, A Novel Oral ALK Tyrosine Kinase Inhibitor in Subjects With ALK+ Advanced or Metastatic NSCLC